Control Strategy Considerations for the Continuous Manufacturing of Low-dose Oral Solid Dosage Formulations.
Saved in:
| Title: | Control Strategy Considerations for the Continuous Manufacturing of Low-dose Oral Solid Dosage Formulations. |
|---|---|
| Authors: | Dumarey M; Global Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Pepparedsleden 1, Mölndal, Gothenburg, 43183, Sweden. melanie.dumarey@astrazeneca.com., Ruiz Samblás C; Global Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Pepparedsleden 1, Mölndal, Gothenburg, 43183, Sweden., Bautista M; Process Analytical Technologies at Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Basel, Switzerland., Kim SS; Formulation Department, Continuous Manufacturing, Vertex Pharmaceuticals, Inc., Boston, USA., Doddridge GD; Product Development Science and Technology, AbbVie, North Chicago, Illinois, USA., Shier AP; Process Engineering & Analytics, GSK, Ware, UK. |
| Source: | The AAPS journal [AAPS J] 2026 May 06; Vol. 28 (3). Date of Electronic Publication: 2026 May 06. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: American Association of Pharmaceutical Scientists Country of Publication: United States NLM ID: 101223209 Publication Model: Electronic Cited Medium: Internet ISSN: 1550-7416 (Electronic) Linking ISSN: 15507416 NLM ISO Abbreviation: AAPS J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1550-7416 |
|---|---|
| DOI: | 10.1208/s12248-026-01250-x |
